Loading...

Paul Henderson

TitleAssoc Prof
InstitutionUniversity of California Davis
Address
vCardDownload vCard

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Gilmore SF, Carpenter TS, Ingólfsson HI, Peters SKG, Henderson P, Blanchette CD, Fischer NO. Lipid composition dictates serum stability of reconstituted high-density lipoproteins: implications for in vivo applications. Nanoscale. 2018 Apr 26; 10(16):7420-7430. PMID: 29564446.
      View in: PubMed
    2. Wang F, Zhang H, Ma AH, Yu W, Zimmermann M, Yang J, Hwang SH, Zhu D, Lin TY, Malfatti M, Turteltaub KW, Henderson P, Airhart S, Hammock BD, Yuan J, de Vere White RW, Pan CX. COX-2/sEH Dual Inhibitor PTUPB Potentiates the Antitumor Efficacy of Cisplatin. Mol Cancer Ther. 2018 Feb; 17(2):474-483. PMID: 29284644.
      View in: PubMed
    3. Zeng SX, Zhu Y, Ma AH, Yu W, Zhang H, Lin TY, Shi W, Tepper CG, Henderson P, Airhart S, Guo JM, Xu CL, deVere White RW, Pan CX. The Phosphatidylinositol 3-Kinase Pathway as a Potential Therapeutic Target in Bladder Cancer. Clin Cancer Res. 2017 Nov 01; 23(21):6580-6591. PMID: 28808038.
      View in: PubMed
    4. Scharadin TM, He W, Yiannakou Y, Tomilov AA, Saldana M, Cortopassi GA, Carraway KL, Coleman MA, Henderson P. Synthesis and biochemical characterization of EGF receptor in a water-soluble membrane model system. PLoS One. 2017; 12(6):e0177761. PMID: 28586369.
      View in: PubMed
    5. Wang SS, Zimmermann M, Zhang H, Lin TY, Malfatti M, Haack K, Turteltaub KW, Cimino GD, de Vere White R, Pan CX, Henderson P. A diagnostic microdosing approach to investigate platinum sensitivity in non-small cell lung cancer. Int J Cancer. 2017 08 01; 141(3):604-613. PMID: 28437852.
      View in: PubMed
    6. Trans DJ, Bai R, Addison JB, Liu R, Hamel E, Coleman MA, Henderson P. Synthesis of two fluorescent GTP?S molecules and their biological relevance. Nucleosides Nucleotides Nucleic Acids. 2017 Jun 03; 36(6):379-391. PMID: 28282254.
      View in: PubMed
    7. Stornetta A, Zimmermann M, Cimino GD, Henderson P, Sturla SJ. DNA Adducts from Anticancer Drugs as Candidate Predictive Markers for Precision Medicine. Chem Res Toxicol. 2017 01 17; 30(1):388-409. PMID: 27936622.
      View in: PubMed
    8. Zimmermann M, Wang SS, Zhang H, Lin TY, Malfatti M, Haack K, Ognibene T, Yang H, Airhart S, Turteltaub KW, Cimino GD, Tepper CG, Drakaki A, Chamie K, de Vere White R, Pan CX, Henderson P. Microdose-Induced Drug-DNA Adducts as Biomarkers of Chemotherapy Resistance in Humans and Mice. Mol Cancer Ther. 2017 Feb; 16(2):376-387. PMID: 27903751.
      View in: PubMed
    9. Scharadin TM, Zhang H, Zimmermann M, Wang S, Malfatti MA, Cimino GD, Turteltaub K, de Vere White R, Pan CX, Henderson P. Diagnostic Microdosing Approach to Study Gemcitabine Resistance. Chem Res Toxicol. 2016 11 21; 29(11):1843-1848. PMID: 27657672.
      View in: PubMed
    10. Gilmore SF, Blanchette CD, Scharadin TM, Hura GL, Rasley A, Corzett M, Pan CX, Fischer NO, Henderson P. Lipid Cross-Linking of Nanolipoprotein Particles Substantially Enhances Serum Stability and Cellular Uptake. ACS Appl Mater Interfaces. 2016 Aug 17; 8(32):20549-57. PMID: 27411034.
      View in: PubMed
    11. Wang S, Zhang H, Scharadin TM, Zimmermann M, Hu B, Pan AW, Vinall R, Lin TY, Cimino G, Chain P, Vuyisich M, Gleasner C, Mcmurry K, Malfatti M, Turteltaub K, de Vere White R, Pan CX, Henderson P. Molecular Dissection of Induced Platinum Resistance through Functional and Gene Expression Analysis in a Cell Culture Model of Bladder Cancer. PLoS One. 2016; 11(1):e0146256. PMID: 26799320; PMCID: PMC4723083.
    12. Jiang S, Pan AW, Lin TY, Zhang H, Malfatti M, Turteltaub K, Henderson P, Pan CX. Paclitaxel Enhances Carboplatin-DNA Adduct Formation and Cytotoxicity. Chem Res Toxicol. 2015 Dec 21; 28(12):2250-2. PMID: 26544157; PMCID: PMC4834887.
    13. He W, Scharadin TM, Saldana M, Gellner C, Hoang-Phou S, Takanishi C, Hura GL, Tainer JA, Carraway KL, Henderson P, Coleman MA. Cell-free expression of functional receptor tyrosine kinases. Sci Rep. 2015 Aug 14; 5:12896. PMID: 26274523; PMCID: PMC4929682.
    14. Zhang H, Li Y, Lin TY, Xiao K, Haddad AS, Henderson P, Jonas BA, Chen M, Xiao W, Liu R, Lam KS, Pan CX. Nanomicelle formulation modifies the pharmacokinetic profiles and cardiac toxicity of daunorubicin. Nanomedicine (Lond). 2014; 9(12):1807-20. PMID: 24628688; PMCID: PMC4167557.
    15. He W, Luo J, Bourguet F, Xing L, Yi SK, Gao T, Blanchette C, Henderson P, Kuhn E, Malfatti M, Murphy WJ, Cheng RH, Lam KS, Coleman MA. Controlling the diameter, monodispersity, and solubility of ApoA1 nanolipoprotein particles using telodendrimer chemistry. Protein Sci. 2013 Aug; 22(8):1078-86. PMID: 23754445; PMCID: PMC3832044.
    16. Cimino GD, Pan CX, Henderson P. Personalized medicine for targeted and platinum-based chemotherapy of lung and bladder cancer. Bioanalysis. 2013 Feb; 5(3):369-91. PMID: 23394702; PMCID: PMC3644565.
    17. Xiao W, Luo J, Jain T, Riggs JW, Tseng HP, Henderson P, Cherry SR, Rowland D, Lam KS. Biodistribution and pharmacokinetics of a telodendrimer micellar paclitaxel nanoformulation in a mouse xenograft model of ovarian cancer. Int J Nanomedicine. 2012; 7:1587-97. PMID: 22605931; PMCID: PMC3352867.
    18. Zhang H, Luo J, Li Y, Henderson P, Wang Y, Wachsmann-Hogiu S, Zhao W, Lam KS, Pan CX. Characterization of high-affinity peptides and their feasibility for use in nanotherapeutics targeting leukemia stem cells. Nanomedicine. 2012 Oct; 8(7):1116-24. PMID: 22197725; PMCID: PMC4577023.
    19. Henderson P, Li T, He M, Zhang H, Malfatti M, Gandara D, Grimminger PP, Danenberg KD, Beckett L, de Vere White RW, Turteltaub KW, Pan CX. A microdosing approach for characterizing formation and repair of carboplatin-DNA monoadducts and chemoresistance. Int J Cancer. 2011 Sep 15; 129(6):1425-34. PMID: 21128223; PMCID: PMC3145006.
    20. Gao T, Blanchette CD, He W, Bourguet F, Ly S, Katzen F, Kudlicki WA, Henderson P, Laurence TA, Huser T, Coleman MA. Characterizing diffusion dynamics of a membrane protein associated with nanolipoproteins using fluorescence correlation spectroscopy. Protein Sci. 2011 Feb; 20(2):437-47. PMID: 21280134; PMCID: PMC3048428.
    21. Wang S, Zhang H, Malfatti M, de Vere White R, Lara PN, Turteltaub K, Henderson P, Pan CX. Gemcitabine causes minimal modulation of carboplatin-DNA monoadduct formation and repair in bladder cancer cells. Chem Res Toxicol. 2010 Nov 15; 23(11):1653-5. PMID: 21028869; PMCID: PMC2987236.
    22. Zhang H, Aina OH, Lam KS, de Vere White R, Evans C, Henderson P, Lara PN, Wang X, Bassuk JA, Pan CX. Identification of a bladder cancer-specific ligand using a combinatorial chemistry approach. Urol Oncol. 2012 Sep; 30(5):635-45. PMID: 20888272; PMCID: PMC4572726.
    23. Henderson P, Evans MD, Cooke MS. Salvage of oxidized guanine derivatives in the (2'-deoxy)ribonucleotide pool as source of mutations in DNA. Mutat Res. 2010 Nov 28; 703(1):11-7. PMID: 20833264; PMCID: PMC2991500.
    24. Hah SS, Henderson P, Turteltaub KW. Towards biomarker-dependent individualized chemotherapy: exploring cell-specific differences in oxaliplatin-DNA adduct distribution using accelerator mass spectrometry. Bioorg Med Chem Lett. 2010 Apr 15; 20(8):2448-51. PMID: 20335033; PMCID: PMC3113698.
    25. Henderson P, Pan CX. Human microdosing for the prediction of patient response. Bioanalysis. 2010 Mar; 2(3):373-6. PMID: 21083245; PMCID: PMC3113695.
    26. Coldwell K, Cutts SM, Ognibene TJ, Henderson P, Phillips DR. Detection of adriamycin-DNA adducts by accelerator mass spectrometry. Methods Mol Biol. 2010; 613:103-18. PMID: 19997880.
      View in: PubMed
    27. Cooke MS, Henderson P, Evans MD. Sources of extracellular, oxidatively-modified DNA lesions: implications for their measurement in urine. J Clin Biochem Nutr. 2009 Nov; 45(3):255-70. PMID: 19902015; PMCID: PMC2771246.
    28. Hah SS, Henderson P, Turteltaub KW. Recent advances in biomedical applications of accelerator mass spectrometry. J Biomed Sci. 2009 Jun 17; 16:54. PMID: 19534792; PMCID: PMC2712465.
    29. Baker SE, Hopkins RC, Blanchette CD, Walsworth VL, Sumbad R, Fischer NO, Kuhn EA, Coleman M, Chromy BA, Létant SE, Hoeprich PD, Adams MW, Henderson P. Hydrogen production by a hyperthermophilic membrane-bound hydrogenase in water-soluble nanolipoprotein particles. J Am Chem Soc. 2009 Jun 10; 131(22):7508-9. PMID: 19449869.
      View in: PubMed
    30. Cappuccio JA, Hinz AK, Kuhn EA, Fletcher JE, Arroyo ES, Henderson P, Blanchette CD, Walsworth VL, Corzett MH, Law RJ, Pesavento JB, Segelke BW, Sulchek TA, Chromy BA, Katzen F, Peterson T, Bench G, Kudlicki W, Hoeprich PD, Coleman MA. Cell-free expression for nanolipoprotein particles: building a high-throughput membrane protein solubility platform. Methods Mol Biol. 2009; 498:273-96. PMID: 18988032.
      View in: PubMed
    31. Coldwell KE, Cutts SM, Ognibene TJ, Henderson P, Phillips DR. Detection of Adriamycin-DNA adducts by accelerator mass spectrometry at clinically relevant Adriamycin concentrations. Nucleic Acids Res. 2008 Sep; 36(16):e100. PMID: 18632763; PMCID: PMC2532723.
    32. Hah SS, Sumbad RA, de Vere White RW, Turteltaub KW, Henderson P. Characterization of oxaliplatin-DNA adduct formation in DNA and differentiation of cancer cell drug sensitivity at microdose concentrations. Chem Res Toxicol. 2007 Dec; 20(12):1745-51. PMID: 18001055.
      View in: PubMed
    33. Chromy BA, Arroyo E, Blanchette CD, Bench G, Benner H, Cappuccio JA, Coleman MA, Henderson P, Hinz AK, Kuhn EA, Pesavento JB, Segelke BW, Sulchek TA, Tarasow T, Walsworth VL, Hoeprich PD. Different apolipoproteins impact nanolipoprotein particle formation. J Am Chem Soc. 2007 Nov 21; 129(46):14348-54. PMID: 17963384.
      View in: PubMed
    34. Hah SS, Mundt JM, Kim HM, Sumbad RA, Turteltaub KW, Henderson P. Measurement of 7,8-dihydro-8-oxo-2'-deoxyguanosine metabolism in MCF-7 cells at low concentrations using accelerator mass spectrometry. Proc Natl Acad Sci U S A. 2007 Jul 03; 104(27):11203-8. PMID: 17592118; PMCID: PMC2040877.
    35. Hah SS, Stivers KM, de Vere White RW, Henderson P. Kinetics of carboplatin-DNA binding in genomic DNA and bladder cancer cells as determined by accelerator mass spectrometry. Chem Res Toxicol. 2006 May; 19(5):622-6. PMID: 16696564.
      View in: PubMed
    36. Hah SS, Kim HM, Sumbad RA, Henderson P. Hydantoin derivative formation from oxidation of 7,8-dihydro-8-oxo-2'-deoxyguanosine (8-oxodG) and incorporation of 14C-labeled 8-oxodG into the DNA of human breast cancer cells. Bioorg Med Chem Lett. 2005 Aug 01; 15(15):3627-31. PMID: 15982874.
      View in: PubMed
    37. Henderson P, Neeley WL, Delaney JC, Gu F, Niles JC, Hah SS, Tannenbaum SR, Essigmann JM. Urea lesion formation in DNA as a consequence of 7,8-dihydro-8-oxoguanine oxidation and hydrolysis provides a potent source of point mutations. Chem Res Toxicol. 2005 Jan; 18(1):12-8. PMID: 15651843.
      View in: PubMed
    38. Henderson P, Delaney JC, Muller JG, Neeley WL, Tannenbaum SR, Burrows CJ, Essigmann JM. The hydantoin lesions formed from oxidation of 7,8-dihydro-8-oxoguanine are potent sources of replication errors in vivo. Biochemistry. 2003 Aug 12; 42(31):9257-62. PMID: 12899611.
      View in: PubMed
    39. Henderson P, Delaney JC, Gu F, Tannenbaum SR, Essigmann JM. Oxidation of 7,8-dihydro-8-oxoguanine affords lesions that are potent sources of replication errors in vivo. Biochemistry. 2002 Jan 22; 41(3):914-21. PMID: 11790114.
      View in: PubMed